Table 3.
Patient clinical and demographic characteristics in patient affected by HBV
| HBV infection | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9* |
| Gender | M | M | F | M | M | F | M | F | F |
| Age [years] | 45 | 59 | 62 | 60 | 72 | 51 | 72 | 61 | 49 |
| HBsAg | Positive | Negative | Negative | Positive | Negative | Negative | Negative | Negative | Negative |
| HBcAb (IgG) | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
| HBsAb | Positive | Positive | Positive | Positive | Negative | Negative | Negative | Negative | Positive |
| HBV-DNA [copies/ml] | Positive | Negative | Negative | Positive | Negative | Negative | Negative | Negative | Negative |
| HBeAg | Positive | Negative | Negative | Negative | – | Negative | – | – | – |
| HbeAb (IgG) | Positive | Positive | Positive | Negative | – | Negative | – | – | – |
| GOT | 50 | 15 | 12 | 45 | 46 | 50 | 37 | 11 | 23 |
| GPT | 45 | 18 | 15 | 52 | 51 | 62 | 40 | 10 | 18 |
| γ-GT | 43 | 20 | 22 | 55 | 48 | 36 | 51 | 13 | 15 |
| Total bilirubin | – | – | – | – | 1.2 | 1.5 | 1.1 | 0.33 | 0.45 |
| Alkaline phosphatase | – | – | – | – | – | 48 | 300 | 257 | 115 |
| LDH | 150 | ||||||||
| Antiviral prophylaxis/therapy for HBV | Tenofovir | Lamivudine (100 mg/die) | Lamivudine (100 mg/die) | Tenofovir | – | – | – | – | – |
| HBV followup | No worsening | No worsening | No worsening | No worsening | No worsening | No worsening | No worsening | No worsening | No worsening |
| Duration of adalimumab therapy [weeks] | 96 | 96 | 96 | 72 | 72 | 96 | 48 | 96 | 48 |
| PASI response | PASI 100 | PASI 100 PASI 75 | PASI 100 | PASI 100 | PASI 100 | PASI 100 | PASI 100 | PASI 75 |
*
Co.infection HBV/TB.